Cocrystal Pharma Net Debt Growth & History (COCP)
Cocrystal Pharma's net debt was −$5.5M for fiscal 2025.
View full Cocrystal Pharma company overviewCocrystal Pharma annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.5M | $2.5M | — |
| 2024 | 2024-12-31 | −$8.1M | $16.4M | — |
| 2023 | 2023-12-31 | −$24.5M | $12.3M | — |
| 2022 | 2022-12-31 | −$36.8M | $21.3M | — |
| 2021 | 2021-12-31 | −$58.2M | −$25.8M | — |
| 2020 | 2020-12-31 | −$32.4M | −$25.8M | — |
| 2019 | 2019-12-31 | −$6.6M | −$4.2M | — |
| 2018 | 2018-12-31 | −$2.4M | −$2.7M | — |
| 2017 | 2017-12-31 | $259,000 | — | — |
| 2015 | 2015-12-31 | $40.7M | −$20.6M | −33.66% |
| 2014 | 2014-12-31 | $61.3M | — | — |
| 2012 | 2012-12-31 | −$3.1M | −$5.4M | — |
| 2011 | 2011-12-31 | $2.3M | $2.3M | +8891.20% |
| 2010 | 2010-12-31 | $25,824 | — | — |
Cocrystal Pharma quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$902,000 | $2.3M | — |
| Q1 2026 | 2026-03-31 | −$3.3M | $1.9M | — |
| Q4 2025 | 2025-12-31 | −$5.5M | $2.5M | — |
| Q3 2025 | 2025-09-30 | −$6.2M | $5.0M | — |
| Q2 2025 | 2025-06-30 | −$3.2M | $13.2M | — |
| Q1 2025 | 2025-03-31 | −$5.3M | $14.8M | — |
| Q4 2024 | 2024-12-31 | −$8.1M | $16.4M | — |
| Q3 2024 | 2024-09-30 | −$11.2M | $18.4M | — |
| Q2 2024 | 2024-06-30 | −$16.4M | $15.9M | — |
| Q1 2024 | 2024-03-31 | −$20.0M | $13.7M | — |
| Q4 2023 | 2023-12-31 | −$24.5M | $12.3M | — |
| Q3 2023 | 2023-09-30 | −$29.6M | $12.1M | — |
| Q2 2023 | 2023-06-30 | −$32.2M | $18.4M | — |
| Q1 2023 | 2023-03-31 | −$33.7M | $20.6M | — |
| Q4 2022 | 2022-12-31 | −$36.8M | $21.3M | — |
| Q3 2022 | 2022-09-30 | −$41.7M | $19.4M | — |
| Q2 2022 | 2022-06-30 | −$50.6M | $16.0M | — |
| Q1 2022 | 2022-03-31 | −$54.3M | −$21.6M | — |
| Q4 2021 | 2021-12-31 | −$58.2M | −$25.8M | — |
| Q3 2021 | 2021-09-30 | −$61.1M | −$29.9M | — |
| Q2 2021 | 2021-06-30 | −$66.6M | −$48.0M | — |
| Q1 2021 | 2021-03-31 | −$32.7M | −$11.7M | — |
| Q4 2020 | 2020-12-31 | −$32.4M | −$25.8M | — |
| Q3 2020 | 2020-09-30 | −$31.1M | −$26.0M | — |
| Q2 2020 | 2020-06-30 | −$18.6M | −$12.1M | — |
| Q1 2020 | 2020-03-31 | −$21.0M | −$13.5M | — |
| Q4 2019 | 2019-12-31 | −$6.6M | −$4.2M | — |
| Q3 2019 | 2019-09-30 | −$5.1M | — | — |
| Q2 2019 | 2019-06-30 | −$6.5M | — | — |
| Q1 2019 | 2019-03-31 | −$7.5M | −$8.3M | — |
| Q4 2018 | 2018-12-31 | −$2.4M | −$2.7M | — |
| Q1 2018 | 2018-03-31 | $790,000 | — | — |
| Q4 2017 | 2017-12-31 | $259,000 | — | — |
| Q4 2015 | 2015-12-31 | $40.7M | −$20.6M | −33.66% |
| Q4 2014 | 2014-12-31 | $61.3M | — | — |
| Q3 2013 | 2013-09-30 | $412,380 | −$732,742 | −63.99% |
| Q2 2013 | 2013-06-30 | −$581,029 | −$1.7M | — |
| Q1 2013 | 2013-03-31 | $1.7M | $705,489 | +69.24% |
| Q4 2012 | 2012-12-31 | −$3.1M | −$5.4M | — |
| Q3 2012 | 2012-09-30 | $1.1M | −$823,153 | −41.82% |
| Q2 2012 | 2012-06-30 | $1.1M | $673,806 | +164.22% |
| Q1 2012 | 2012-03-31 | $1.0M | — | — |
| Q4 2011 | 2011-12-31 | $2.3M | $2.3M | +8891.20% |
| Q3 2011 | 2011-09-30 | $2.0M | — | — |
| Q2 2011 | 2011-06-30 | $410,315 | — | — |
| Q4 2010 | 2010-12-31 | $25,824 | — | — |
Cocrystal Pharma net debt trends
Over the last five fiscal years, Cocrystal Pharma's net debt increased from −$32.4M to −$5.5M, a change of $26.9M. The latest reported quarter, Q2 2026, shows −$902,000.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cocrystal Pharma source filings ↗